Delivering novel therapeutics for the treatment of autoimmune diseases
SuppreMol, a privately held biopharmaceutical Company, is developing novel protein therapeutics for the treatment of autoimmune and chronic inflammatory diseases as well as allergies.
SuppreMol’s core competence is around the function and modulation of the Fcy Receptors in particular FcyRIIB, the only member of the Fcy Receptor family with inhibitory function on a variety of immune cells. The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry.
SuppreMol is following two distinct novel strategies to treat autoimmune diseases: the Company has developed SM101, the soluble extracellular domain of FcyRIIB (sFcγRIIB), with the objective to isolate and block immune complexes during an autoimmune response and thereby preventing re-triggering of the immune system. To gain proof of concept, SuppreMol has performed Phase II clinical trials with SM101 in Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE).
SuppreMol's second strategy to tackle diseases of the immune system is to enhance the inhibitory potential of FcyRIIB on cells directly. For that purpose SuppreMol has developed a monoclonal antibody framework providing a set of highly selective immunoregulators directly modulating Fc Receptors without blocking its natural function. The resulting antibodies, SM201, SM211 and SM301, may represent a novel and superior option for the treatment of autoimmune diseases, chronic inflammations and allergies.